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Introduction
BAY 58–2667 is a novel activator of the soluble guanylyl
cyclase (sGC) with vasodilatory properties particularly in
diseased blood vessels [1]. BAY 58–2667 is currently
under clinical development for the treatment of acute
decompensated heart failure.
Within the scope of a Safety Pharmacology study, effects
on cardiovascular function and ECG were examined in
anesthetized Beagle dogs after intravenous administra-
tion. Infusion rates of this placebo-controlled study were
chosen to cover approximately the 10 fold of therapeutic
plasma levels.
Materials and methods
Nine female and male Beagle dogs (age 1.5–3 years, body
weight 10 – 15 kg) were anesthetized (neuroleptic
anesthesia with droperidol/fentanyl) and artificially ven-
tilated (N2O/O2) [2]. Hemodynamic parameters systolic
and diastolic arterial blood pressure (BPS, BPD), left ven-
tricular systolic and end diastolic pressure (LVP, LVEDP),
left ventricular dP/dt (LVdP/dt), cardiac output (CO), cen-
tral venous pressure (CVP), and heart rate (HR) were
measured continuously. Total peripheral resistance (TPR)
was calculated as mean arterial pressure (BPM) divided by
cardiac output. ECG was recorded with standard lead II
and RR, PQ, QRS, and QT interval were evaluated. QT was
corrected for heart rate by Fridericia's formula (QTcF).
Groups of n = 3 dogs received 3 cumulative infusion steps
of placebo (1 mM Tris buffer at pH 8.6–8.8 in saline,
0.44–0.67–3.33 ml/kg/h) or BAY 58–2667 at low (1–5–
25 μg/kg/h) or at high (5–15–45 μg/kg/h) infusion rates.
Infusion rates were consecutively increased every hour fol-
lowed by a 2 hour washout period after stop of the final
infusion step.
Systemic exposure was determined in plasma after protein
precipitation and separation by high-pressure liquid chro-




BAY 58–2667 caused a plasma concentration dependent
reduction of LVEDP (-98%) and CVP (-54%) followed by
a vasodilation (marked reduction of TPR by -48%) which
was accompanied by counter regulation with increase of
HR (+113%) and LV dP/dt (+21%) as a consequence of
sympathetic activation. Mean plasma levels of 17.8 μg/L
at low infusion rates and 25.2 μg/L at high infusion rates
were obtained (Table 1).
Hemodynamic effects of low and high infusion rates of
BAY 58–2667 (placebo normalized data, relative to base-
line values, means of n = 3) at end of each infusion step
and end of 2 hour washout period with corresponding
plasma levels.
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Besides effects which are attributable to increased heart
rate (shortening of PQ and QT interval) the ECG was not
significantly affected. In particular no effects on QTcF
interval were seen up to highest mean plasma levels of 25
μg/L (=0.5 nMunbound) whereas cardiovascular effects were
seen already at 3 μg/L (=0.06 nMunbound). Electrophysio-
logical in vitro investigations (in-house data) demon-
strated that BAY 58–2667 elicited no effects on dog
Purkinje fiber action potentials up to 1000 nM and only
slight inhibition of hERG K+ current (IC50 >1000 nM).
Summary
The sGC activator BAY 58–2667 was intravenously
administered to anesthetized dogs at a dose-range of 1 –
45 μg/kg/hour yielding mean plasma levels of up 25 μg/L.
Observed effects are: (1) Threshold of cardiovascular
effects in dogs at plasma levels of 3 μg/L comparable to
that in healthy volunteers (2.5 μg/L); (2) Reduction of
ventricular pre- and afterload (decrease of CVP, LVEDP,
BPM); (3) Marked vasodilation (up to 48% TPR reduc-
tion); (4) No evidence for risk of QT prolongation.
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1 60 2 -2 -2 -2 0 -8 -3 -2 -6 3 0.9
5 120 4 -14 -4 -10 -7 -40 -1 -24 -3 -5 3.4
25 180 34 -26 -2 -14 -9 -67 21 -43 27 -23 17.8
washout 300 19 -22 2 -11 -11 -22 1 -9 10 -18 0.2


























5 60 32 -14 -4 -9 -8 -24 16 -24 13 -18 2.9
15 120 56 -34 -16 -26 -18 -65 9 -37 36 -39 8.8
45 180 113 -47 -21 -31 -18 -98 17 -54 73 -48 25.2
washout 300 34 -31 -7 -20 -20 -39 -19 -27 15 -29 0.3Page 2 of 2
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